TD Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.89M | Buy |
34,973
+400
| +1% | +$59.3K | 0.01% | 778 |
|
|
2026
Q1 | $4.55M | Sell |
34,573
-36,500
| -51% | -$4.84M | ﹤0.01% | 813 |
|
|
2025
Q4 | $10.1M | Sell |
71,073
-32,550
| -31% | -$4.72M | 0.01% | 652 |
|
|
2025
Q3 | $14.5M | Sell |
103,623
-19,700
| -16% | -$2.67M | 0.01% | 569 |
|
|
2025
Q2 | $15.5M | Buy |
123,323
+140
| +0.1% | +$16.1K | 0.01% | 540 |
|
|
2025
Q1 | $13.6M | Buy |
123,183
+21,400
| +21% | +$2.71M | 0.01% | 576 |
|
|
2024
Q4 | $13.9M | Sell |
101,783
-17,010
| -14% | -$2.1M | 0.01% | 584 |
|
|
2024
Q3 | $13.7M | Sell |
118,793
-21,474
| -15% | -$2.94M | 0.01% | 589 |
|
|
2024
Q2 | $19.3M | Sell |
140,267
-3,167
| -2% | -$434K | 0.02% | 503 |
|
|
2024
Q1 | $19.8M | Buy |
143,434
+39,215
| +38% | +$5.36M | 0.02% | 490 |
|
|
2023
Q4 | $13.7M | Buy |
104,219
+48,521
| +87% | +$5.59M | 0.01% | 562 |
|
|
2023
Q3 | $6.27M | Buy |
55,698
+20,360
| +58% | +$2.14M | 0.01% | 676 |
|
|
2023
Q2 | $3.33M | Sell |
35,338
-1,558
| -4% | -$152K | ﹤0.01% | 829 |
|
|
2023
Q1 | $3.73M | Sell |
36,896
-1,262
| -3% | -$131K | ﹤0.01% | 817 |
|
|
2022
Q4 | $4.56M | Sell |
38,158
-99,494
| -72% | -$11.7M | 0.01% | 769 |
|
|
2022
Q3 | $14.1M | Sell |
137,652
-95,700
| -41% | -$9.71M | 0.02% | 494 |
|
|
2022
Q2 | $22.7M | Sell |
233,352
-38,082
| -14% | -$3.51M | 0.03% | 406 |
|
|
2022
Q1 | $25.4M | Sell |
271,434
-12,395
| -4% | -$1.05M | 0.02% | 425 |
|
|
2021
Q4 | $24.2M | Buy |
283,829
+122,495
| +76% | +$11.3M | 0.02% | 470 |
|
|
2021
Q3 | $15.5M | Sell |
161,334
-10,500
| -6% | -$992K | 0.02% | 536 |
|
|
2021
Q2 | $16M | Sell |
171,834
-23,251
| -12% | -$2.23M | 0.02% | 535 |
|
|
2021
Q1 | $19M | Buy |
195,085
+14,930
| +8% | +$1.57M | 0.02% | 479 |
|
|
2020
Q4 | $17.3M | Buy |
180,155
+5,956
| +3% | +$575K | 0.02% | 463 |
|
|
2020
Q3 | $16.8M | Buy |
174,199
+7,501
| +4% | +$868K | 0.02% | 426 |
|
|
2020
Q2 | $20.3M | Buy |
166,698
+19,341
| +13% | +$2.14M | 0.03% | 358 |
|
|
2020
Q1 | $12.8M | Sell |
147,357
-21,983
| -13% | -$2.15M | 0.02% | 424 |
|
|
2019
Q4 | $18.2M | Buy |
169,340
+12,500
| +8% | +$1.31M | 0.03% | 403 |
|
|
2019
Q3 | $14.1M | Buy |
156,840
+73,400
| +88% | +$6.86M | 0.02% | 435 |
|
|
2019
Q2 | $7.04M | Sell |
83,440
-2,700
| -3% | -$222K | 0.01% | 607 |
|
|
2019
Q1 | $7.59M | Sell |
86,140
-10,899
| -11% | -$911K | 0.01% | 587 |
|
|
2018
Q4 | $6.93M | Sell |
97,039
-40,000
| -29% | -$3.83M | 0.01% | 572 |
|
|
2018
Q3 | $16.8M | Buy |
137,039
+5,540
| +4% | +$629K | 0.02% | 425 |
|
|
2018
Q2 | $12.9M | Buy |
131,499
+2,100
| +2% | +$188K | 0.02% | 469 |
|
|
2018
Q1 | $10.7M | Buy |
129,399
+3,400
| +3% | +$287K | 0.02% | 507 |
|
|
2017
Q4 | $9.78M | Sell |
125,999
-26,031
| -17% | -$1.78M | 0.01% | 526 |
|
|
2017
Q3 | $9.32M | Sell |
152,030
-4,570
| -3% | -$241K | 0.01% | 526 |
|
|
2017
Q2 | $7.2M | Buy |
156,600
+69,100
| +79% | +$3.35M | 0.01% | 593 |
|
|
2017
Q1 | $3.79M | Sell |
87,500
-45,395
| -34% | -$1.94M | 0.01% | 764 |
|
|
2016
Q4 | $5.14M | Sell |
132,895
-67,105
| -34% | -$3.04M | 0.01% | 671 |
|
|
2016
Q3 | $10.1M | Sell |
200,000
-29,200
| -13% | -$1.45M | 0.02% | 524 |
|
|
2016
Q2 | $10.4M | Sell |
229,200
-2,600
| -1% | -$120K | 0.02% | 501 |
|
|
2016
Q1 | $9.17M | Sell |
231,800
-6,900
| -3% | -$274K | 0.02% | 519 |
|
|
2015
Q4 | $13.5M | Buy |
238,700
+15,500
| +7% | +$788K | 0.03% | 416 |
|
|
2015
Q3 | $8.88M | Sell |
223,200
-15,400
| -6% | -$744K | 0.02% | 488 |
|
|
2015
Q2 | $11.4M | Sell |
238,600
-4,500
| -2% | -$191K | 0.02% | 472 |
|
|
2015
Q1 | $9.65M | Buy |
243,100
+30,800
| +15% | +$1.1M | 0.02% | 504 |
|
|
2014
Q4 | $4.74M | Buy |
212,300
+13,900
| +7% | +$263K | 0.01% | 680 |
|
|
2014
Q3 | $3.11M | Sell |
198,400
-8,500
| -4% | -$127K | 0.01% | 746 |
|
|
2014
Q2 | $3.07M | Sell |
206,900
-9,900
| -5% | -$140K | 0.01% | 756 |
|
|
2014
Q1 | $3.49M | Buy |
216,800
+39,400
| +22% | +$674K | 0.01% | 741 |
|
|
2013
Q4 | $1.66M | Sell |
177,400
-3,100
| -2% | -$30.3K | ﹤0.01% | 833 |
|
|
2013
Q3 | $2.04M | Buy |
180,500
+34,900
| +24% | +$480K | ﹤0.01% | 798 |
|
|
2013
Q2 | $1.95M | Buy |
+145,600
| New | +$1.79M | ﹤0.01% | 769 |
|
Other funds holding NBIX
TD Asset Management's NBIX Position: Q2 2026 in Review
TD Asset Management increased its Neurocrine Biosciences (NBIX) stake by 1.2% in Q2 2026, buying an estimated $59.3K and bringing the position to 34,973 shares worth $5.89M. The position accounts for 0.01% of the portfolio, ranked #778.
TD Asset Management first reported a position in NBIX in Q2 2013 and has held it in 53 quarters since. The position peaked at $25.4M in Q1 2022. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- TD Asset Management held 34,973 shares of Neurocrine Biosciences worth $5.89M as of Q2 2026.
- TD Asset Management bought 400 Neurocrine Biosciences shares in Q2 2026, an estimated $59.3K.
- Neurocrine Biosciences made up 0.01% of TD Asset Management's portfolio in Q2 2026, its #778 holding.
- TD Asset Management first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 53 quarters since.
- TD Asset Management's Neurocrine Biosciences position peaked at $25.4M in Q1 2022.
- 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.